Clinical Research Directory

Inclusion Criteria: * Age ≥65 years * Has nocturia as determined by ICS criteria (ICIQ-N) * Has Nocturia, after 4 weeks of conservative treatment (fluid advice, leg elevation, sodium restriction, medication review, mild compression stockings where relevant), indicates a score of ≥4 on question 4b of the validated ICIQ Nocturia module \[https://iciq.net/iciq-n\] - (indication of bother rating of 4-10) * Participants with prior treatment for concomitant OAB should have been on stable doses of therapy for 12 weeks prior to inclusion. Exclusion Criteria: * Participant has a 24h polyuria (\>3L), measured by a 7-day bladder diary * Participant has a post-void residual (\>250mL), measured by ultrasound following void from a comfortably full bladder * Participant has an acute symptomatic UTI (can be treated and rescreened for inclusion) * The participant has known untreated sleep apnoea, or highly likely OSA according to the validated STOP-BANG questionnaire (score 5-8) * The participant has significant heart failure (NYHA C/D) * The participant has severe renal impairment (eGFR \<30mL/min), severe hepatic impairment (Child-Pugh class 3) * The participant is taking hypnotics * The participant is taking strong CYP3A inducers such as rifampin, carbamazepine, St. John's wort * The participant has a known drug allergy to Lemborexant or its constituents * The participant has cognitive impairment of a degree which, in the opinion of the investigator, is likely to impair the ability to adhere to trial requirements * The participant is unwilling to abstain from alcohol consumption for the period of the study * Other condition(s) which would preclude inclusion.